logo
State's health benefits agency running out of money

State's health benefits agency running out of money

Yahoo17-04-2025
BOSTON (SHNS) – The state agency that oversees health insurance for 460,000 public employees, retirees and their dependents is on track to run out of money to pay claims on May 12, a full seven weeks before the end of the fiscal year.
During a briefing to Group Insurance Commission members Thursday, Executive Director Matthew Veno said rising provider prices and increased utilization of prescription benefits, including for GLP-1 weight loss drugs, had caused the commission to run an average $20 million monthly deficit this fiscal year.
With the fiscal year set to end June 30, the commission is counting on taxpayers to cover its deficit and has a $240 million appropriation request pending before the Legislature.
The appropriation was the largest single request in a $756 million spending bill Gov. Maura Healey filed in early April.
The House Ways and Means Committee released its fiscal 2026 annual budget Wednesday, and Veno expressed hope Thursday that the panel will quickly turn attention to the supplemental budget. He said he was working with Healey's team to make sure lawmakers understand 'the urgency of moving this legislation.'
'What we want to do is avoid disruption to our members, our health plans and to the providers that rely on our prompt payment of claims,' he said. 'And we are likewise in the process of meeting with our health plans to make sure that we're prepared to manage any disruption that may come along our way if there's delayed action.'
While predicting timetables for legislative action in Massachusetts is perilous, Veno said he believed that it was 'unlikely that the supplemental budget will not be enacted in a timely manner.'
'But it is certainly a cause on my part for concern and focus since by our current projections and our current appropriation is sufficient to make claims only through the 12th of May 2025,' he added.
Commission members had no questions for Veno about the deficit, apart from a Bobbi Kaplan inquiry about whether the GIC might need to adjust its fiscal 2026 budget request to reflect the higher fiscal 2025 costs. Veno said no adjustment is necessary.
'While we have been consistently running a deficiency, it's been pretty consistent. So we were able to build an FY '26 budget that reflects those trends,' he said.
There's been steady growth in the major state spending account in recent years, adding pressure in the overall state budget and creating another touchpoint for those who believe stronger action is needed to address health-related costs.
The GIC's 'plan premium and costs' are projected at $2.16 billion for fiscal 2025 and Healey requested a $2.4 billion allocation for fiscal 2026, a funding level also recommended by the House Ways and Means Committee. Expenses from the account totaled $1.83 billion in fiscal 2022, according to state finance documents.
The GIC provides health insurance to state employees and retirees and their dependents and survivors. It has 280,000 subscribers and 460,000 members.
In January, Veno flagged the agency's budget shortfalls as a going concern.
'This is the largest variance that we've seen in at least a decade, and this is consistent across all of our plans, and is driven primarily by rising provider prices and a couple of other topics,' he said at the time. He added, 'We don't know where this is going to head. My concern is that it is a persistent and steady trend going forward.'
The agency has a 'good list of candidates' for its open chief financial officer position, Veno said, an the annual enrollment process is 'going smoothly' with policy holders shopping around given increasing premiums. The commission also plans to offer a report in May on out-of-pocket spending trends.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Viking Therapeutics stock falls 37% on high dropout rate in obesity trial
Viking Therapeutics stock falls 37% on high dropout rate in obesity trial

Yahoo

time39 minutes ago

  • Yahoo

Viking Therapeutics stock falls 37% on high dropout rate in obesity trial

-- Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages. The trial demonstrated that Viking's oral tablet formulation of VK2735, a dual GLP-1 and GIP receptor agonist, met its primary endpoint with patients losing up to 12.2% of body weight after 13 weeks compared to 1.3% for placebo. Despite the weight loss efficacy, the 28% treatment discontinuation rate among patients receiving VK2735 versus 18% for placebo raised significant concerns among investors and analysts. Mizuho analyst Jared Holz highlighted competitive disadvantages compared to Eli Lilly's offerings: "Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range --- but over 72-weeks; A much longer trial, and therefor LLY looks far better head-to-head. This probably shutters hope for VKTX a bigtime player in the oral obesity market over the near to medium term." JPMorgan (NYSE:JPM) analyst Hardik Parikh offered a more balanced view, noting, "In 13 weeks, the three highest-dosing arms of 60/90/120mg showed avg pbo-adj weight loss of ~7.5%, 10%, 11%, which we think is very strong compared with other orals in development. Tolerability overall was manageable, but it was worse than we expected based on the ph1 performance." Parikh added that while the adverse event profile wasn't as clean as in Phase 1 trials, "we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile." Viking reported that 99% of gastrointestinal-related adverse events were mild or moderate. The company also highlighted an exploratory maintenance dosing arm showing weight loss could be maintained at lower doses. The major adverse events included vomiting rates of 20-35% in the three highest dose arms compared to about 10% for placebo, and nausea rates of approximately 58% for patients on treatment versus 48% for placebo. Related articles Viking Therapeutics stock falls 37% on high dropout rate in obesity trial Tesla robotaxi trial impresses, pricing power clear: William Blair Palo Alto Networks gains after strong earnings and Bank of America upgrade

Ozempic price slashed following Donald Trump's demands - will it impact the UK cost?
Ozempic price slashed following Donald Trump's demands - will it impact the UK cost?

Yahoo

timean hour ago

  • Yahoo

Ozempic price slashed following Donald Trump's demands - will it impact the UK cost?

Diabetes patients in the US will now be able to purchase Ozempic for half its usual cost. Novo Nordisk, a Danish pharmaceutical company, said on Monday that it would be providing the drug through its direct pharmacy service for $499 (£369) per month, instead of just under $1,000 per month. The drug giant said it had made a deal with healthcare firm GoodRx to make Wegovy, its obesity drug, available at this price in over 70,000 pharmacies nationwide. It comes after Novo Nordisk saw sales plummet last month, after competition ramped up in the US. The company said the profit warning came as a result of 'persistent use' of compounded – or copycat – versions of its drugs, as well as 'slower-than-expected market expansion and competition'. It has faced serious competition from Mounjaro, Eli Lilly's rival weight loss jab, as well as what it described as 'unsafe and unlawful mass compounding' in the market as weight loss and diabetes drugs have soared in popularity. Ozempic and Wegovy both contain glucagon-like peptide-1 (GLP-1). It works by stimulating insulin secretion, which is why it helps patients with type 2 diabetes, but it also signals fullness to the brain. Wegovy only triggers the GLP-1 receptor in the brian but Mounjaro works on both GLP-1 and GIP receptors, which can lead to more weight loss. In March, Novo Nordisk reduced the cost of Wegovy for cash-paying patients, but now people without health insurance will be able to purchase it for this price. Trump's critique The move comes just weeks after President Donald Trump criticised GLP-1 agonists for being more expensive in the US than in other countries, adding that he would 'slash the cost of prescription drugs' by 80 per cent. Last month, Trump wrote to pharmaceutical leaders demanding that they 'negotiate harder with foreign freeloading nations'. He said: 'increased revenues abroad must be repatriated to lower drug prices for American patients and taxpayers'. He's since upped that number, saying he would cut drug prices up to '1,500 percent,' which is mathematically impossible without entering negative numbers. He also said that European nations were 'unfairly shifting the cost burden onto American patients' by using their healthcare services to put pressure on US pharma companies to accept lower prices. Novo Nordisk said that the price cut was unrelated to discussions with the US government. Pfizer CEO Albert Boula has said he and other pharma companies are in talks about making their drugs available at a lower cost. Will it impact the UK cost? In the UK, patients can buy a four-week supply of Ozempic for between £119 and £190 from online pharmacies. Novo Nordisk said it has no plans to rise UK prices, despite pressure from Trump. In a statement, it said it would continue to focus 'on supporting patients, and we are committed to ensuring that our medicines are not only innovative but also accessible and affordable for those who need them most'. However, last week, weight-loss drugmaker Eli Lilly said it would increase UK prices by as much as 170pc due to concerns about unfair pricing. The company said obesity drug Mounjaro would rise in price from Sept 1 in order to address 'pricing inconsistencies compared to other developed countries, including in Europe'. The company's weight-loss jab will cost between £133 and £330 per injection (depending on dosage) in the UK. CheqUp, a weight-loss jab provider, reported that sales of Wegovy increased more than 500pc, following the Eli Lilly announcement.

knownwell Strengthens Regional Footprint, Opens Second Clinic in the Greater Boston Area
knownwell Strengthens Regional Footprint, Opens Second Clinic in the Greater Boston Area

Yahoo

timean hour ago

  • Yahoo

knownwell Strengthens Regional Footprint, Opens Second Clinic in the Greater Boston Area

The Company Unveils its Seventh New Weight-Inclusive Care Location in the Last Year, Increasing Patient Population by Nearly 400% BOSTON, August 19, 2025--(BUSINESS WIRE)--knownwell, an in-person and virtual weight-inclusive primary care and metabolic health company that opened its flagship clinic in Needham, Massachusetts in 2023, announces the deepening of its physical presence in the greater Boston area. As the company continues to increase access to weight-inclusive care across the country, the opening of a new clinic will provide additional opportunities for in-person engagement with locally based patients near Woburn, Massachusetts. The news comes on the heels of knownwell opening seven new clinics in the last year, including one in Dallas and six in Chicago, to provide in-person care in the Midwest and South Central regions. It also follows the company's launch of virtual metabolic care to patients in all 50 U.S. states. Today, more than half of adults in Massachusetts are affected by overweight or obesity. In Woburn alone, 1 in 4 adults has obesity. With few options for comprehensive metabolic care in the area, the addition of a new local clinic comes at a pivotal time to support those in need. "Boston has always held a special place in our story – it is where our mission began, and where we proved that weight-inclusive care can change lives," said Brooke Boyarsky Pratt, CEO and Co-Founder of knownwell. "This expansion isn't just about growth; it's about meeting an urgent need in a community that has inspired us from day one. Expanding our footprint here reflects both the significant need and our dedication to delivering accessible, whole-person care to help more people in Massachusetts achieve lasting health." The Woburn clinic arrives amid the demand for GLP-1 medications surging and the cost of treatment continuing to rise, creating new barriers for patients seeking effective, long-term solutions for obesity and overweight. By growing its presence in Massachusetts, the company aims to bridge this gap, delivering treatment that combines clinical, nutritional, and behavioral support to ensure patients receive the full spectrum of care they need to improve their health and quality of life. "When I moved to Massachusetts decades ago, it was to be part of a movement to treat obesity like the chronic disease it is – with science, compassion, and comprehensive care. This expansion in greater Boston is the next chapter in that mission, with knownwell leading the charge," said Chief Medical Officer and Co-Founder of knownwell, Dr. Angela Fitch. "By increasing access to integrated treatment, we're not just helping individuals improve their health but taking meaningful steps toward reducing obesity rates across the country." With the new opening, knownwell will additionally onboard Dr. Giovanna Leddy, President of the New England Obesity Society, as the new Market Medical Director, overseeing both the Woburn and Needham practices. Dr. Leddy serves as the Associate Director of the Social Justice Pathway within the Internal Medicine Residency Program at Beth Israel Deaconess Medical Center and currently practices Obesity Medicine at Atrius Health. She is also a Clinical Instructor in Medicine at Harvard Medical School. knownwell is on a mission to make weight-inclusive healthcare more accessible. It offers full-coverage care, including metabolic health services, comprehensive primary care, nutrition counseling, and behavioral health services online and in person, and accepts insurance. To learn more about knownwell, visit ABOUT KNOWNWELL: knownwell is built for the millions of Americans who have been told that their weight is the problem, regardless of their unique health concerns. Stigmatizing patients does not promote wellness, and in fact, leads to worse health outcomes. knownwell practices evidence-based medicine that supports a patient's unique goals, creating a healthcare home for patients with overweight and obesity. To learn more, visit View source version on Contacts Karalyn HooverSolCommsknownwell@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store